TCL Archive Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML December 28, 2007
TCL Archive Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival July 27, 2012